Literature DB >> 25663793

Unfavorable outcome of antiviral therapy in cytomegalovirus-positive ulcerative colitis may be due to inappropriate study inclusion in meta-analysis.

Xiao-Wei Wu1, Miao-Fang Yang1, Nan Li1, Fang-Yu Wang1.   

Abstract

Some previous articles reported that antiviral treatment was effective to reduce the colectomy rate in ulcerative colitis (UC) patients with cytomegalovirus (CMV) infection. Kopylov et al recently carried out a systematic review and meta-analysis to evaluate the impact of antiviral therapy on CMV-positive UC. The results showed that patients who received antiviral treatment had a higher risk of 30-d colectomy. We found that in this meta-analysis, some studies were inappropriately included, leading to an unfavorable outcome of anti-CMV therapy in UC patients.

Entities:  

Keywords:  Antiviral therapy; Colectomy; Cytomegalovirus; Meta-analysis; Ulcerative colitis

Mesh：

Substances：

Year:  2015        PMID： 25663793      PMCID： PMC4316116          DOI： 10.3748/wjg.v21.i5.1689

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  6 in total

1.  The absence of large ulcer predicts latent cytomegalovirus infection in ulcerative colitis with positive mucosal viral assay.

Authors:  Mika Omiya; Mitsunobu Matsushita; Toshihiro Tanaka; Seiji Kawamata; Kazuichi Okazaki
Journal:  Intern Med       Date:  2010-11-01       Impact factor: 1.271

Review 2.  Cytomegalovirus: a probable cause of steroid-refractory ulcerative colitis.

Authors:  Meng Xue; Shu Jie Chen; Liang Jing Wang; Ying Du; Jian Min Si
Journal:  J Dig Dis       Date:  2013-04       Impact factor: 2.325

3.  Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

Authors:  J F Rahier; F Magro; C Abreu; A Armuzzi; S Ben-Horin; Y Chowers; M Cottone; L de Ridder; G Doherty; R Ehehalt; M Esteve; K Katsanos; C W Lees; E Macmahon; T Moreels; W Reinisch; H Tilg; L Tremblay; G Veereman-Wauters; N Viget; Y Yazdanpanah; R Eliakim; J F Colombel
Journal:  J Crohns Colitis       Date:  2014-03-06       Impact factor: 9.071

4.  The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study.

Authors:  You Sun Kim; Young-Ho Kim; Joo Sung Kim; Jae Hee Cheon; Byong Duk Ye; Sung-Ae Jung; Young Sook Park; Chang Hwan Choi; Byung Ik Jang; Dong Soo Han; Suk-Kyun Yang; Won Ho Kim
Journal:  J Clin Gastroenterol       Date:  2012-01       Impact factor: 3.062

5.  Cytomegalovirus positive ulcerative colitis: A single center experience and literature review.

Authors:  Uri Kopylov; Gila Sasson; Bella Geyshis; Michal Tepperberg Oikawa; Iris Barshack; Rami Eliakim; Shomron Ben-Horin
Journal:  World J Gastrointest Pathophysiol       Date:  2013-02-15

Review 6.  Antiviral therapy in cytomegalovirus-positive ulcerative colitis: a systematic review and meta-analysis.

Authors:  Uri Kopylov; Noa Eliakim-Raz; Andrew Szilagy; Ernest Seidman; Shomron Ben-Horin; Lior Katz
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742
  6 in total
  3 in total

1.  The detection of the cytomegalovirus DNA in the colonic mucosa of patients with ulcerative colitis is associated with increased long-term risk of proctocolectomy: results from an outpatient IBD clinic.

Authors:  Wiebke Schenk; Tobias Klugmann; Annett Borkenhagen; Chris Klecker; Peter Dietel; Ralf Kirschner; Eckhardt Schneider; Tony Bruns; Andreas Stallmach; Niels Teich
Journal:  Int J Colorectal Dis       Date:  2018-11-30       Impact factor: 2.571

2.  Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences.

Authors:  Hiroshi Nakase; Hans Herfarth
Journal:  Inflamm Intest Dis       Date:  2016-01-23

3.  Identification of clinically relevant cytomegalovirus infections in patients with inflammatory bowel disease.

Authors:  Nils Wethkamp; Eva-Maria Nordlohne; Volker Meister; Ulf Helwig; Michael Respondek
Journal:  Mod Pathol       Date:  2017-12-01       Impact factor: 7.842
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.